Therapist and computer‐based brief interventions for drug use within a randomized controlled trial: effects on parallel trajectories of alcohol use, cannabis use and anxiety symptoms by Drislane, Laura E. et al.
Therapist and computer-based brief interventions for
drug use within a randomized controlled trial: effects on
parallel trajectories of alcohol use, cannabis use and
anxiety symptoms
Laura E. Drislane1,2 , Rebecca Waller1,3, Meghan E. Martz1, Erin E. Bonar1 , Maureen A. Walton1,
Stephen T. Chermack1,4,5 & Frederic C. Blow1,4
Addiction Center, Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA,1 Department of Psychology, Sam Houston State University, Huntsville, TX,
USA,2 Department of Psychology, University of Pennsylvania, Philadelphia, PA, USA,3 Center for Clinical Management Research, Health Services Research and
Development, Veterans Health Administration, Ann Arbor, MI, USA4 and Mental Health Service, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, USA5
ABSTRACT
Background and Aims Despite their high comorbidity, the effects of brief interventions (BI) to reduce cannabis use, al-
cohol use and anxiety symptoms have received little empirical attention. The aims of this study were to examine whether a
therapist-delivered BI (TBI) or computer-guided BI (CBI) to address drug use, alcohol consumption (when relevant) and
HIV risk behaviors, relative to enhanced usual care (EUC), was associated with reductions in parallel trajectories of alcohol
use, cannabis use and anxiety symptoms, and whether demographic characteristics moderated reductions over time.
Design Latent growth curve modeling was used to examine joint trajectories of alcohol use, cannabis use and anxiety
symptoms assessed at 3, 6 and 12 months after baseline enrollment. Setting Hurley Medical Center Emergency Depart-
ment (ED) in Flint, MI, USA. Participants The sample was 780 drug-using adults (aged 18–60 years; 44% male; 52%
black) randomly assigned to receive either a TBI, CBI or EUC through the HealthiER You study. Interventions and
comparator ED-delivered TBI and CBIs involved touchscreen-delivered and audio-assisted content. The TBI was admin-
istered by a Master’s-level therapist, whereas the CBI was self-administered using a virtual health counselor. EUC included
a review of health resources brochures in the ED.Measurements Assessments of alcohol use (10-item Alcohol Use Dis-
orders Identification Test), cannabis use (past 30-day frequency) and anxiety symptoms (Brief Symptom Inventory-18) oc-
curred at baseline and 3-, 6- and 12-month follow-up. Findings TBI, relative to EUC, was associated with significant
reductions in cannabis use [B = –0.49, standard error (SE) = 0.20, P < 0.05) and anxiety (B = –0.04, SE = 0.02,
P< 0.05), but nomain effect for alcohol use. Two of 18moderation tests were significant: TBI significantly reduced alcohol
use among males (B = –0.60, SE = 0.19, P < 0.01) and patients aged 18–25 years in the TBI condition showed signifi-
cantly greater reductions in cannabis use relative to older patients (B = –0.78, SE = 0.31, P< 0.05). Results for CBI were
non-significant. Conclusions Emergency department-based therapist-delivered brief interventions to address drug use,
alcohol consumption (when relevant) and HIV risk behaviors may also reduce alcohol use, cannabis use and anxiety over
time, accounting for the overlap of these processes.
Keywords Alcohol, anxiety, brief intervention, cannabis, emergency department, latent growth curve modeling.
Correspondence to: Laura E. Drislane, Department of Psychology, Sam Houston State University, 1901 Avenue I, Room 308, Huntsville, TX, 77340, USA.
Email: lauradrislane@gmail.com
Submitted 15 January 2019; initial review completed 11 March 2019; final version accepted 2 August 2019
INTRODUCTION
Alcohol and drug misuse quadruple the risk of emergency
department (ED) injury-related admissions world-wide
[1,2]. Thus, the ED provides an invaluable setting for
screening, brief intervention and referral to treatment
(SBIRT) for substance use. The efficacy of SBIRT in
health-care settings, including the ED, however, has been
mixed. Prior studies have supported the efficacy of alcohol
brief interventions (BI) [3–5], although BIs targeting drug
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use have yielded inconsistent results [6–11] and the inclu-
sion of boosters has shown no effect [12,13]. Further, the
impact of alcohol and drug BIs on comorbid mental health
problems (e.g. anxiety) is largely unknown.
More recently,HealthiERYou [14] tested the efficacy of a
computer-guided BI (CBI) and a therapist-delivered BI
(TBI) relative to enhanced usual care (EUC) for drug-using
adults presenting to an ED in a predominately low-income,
urban community. The BIs were based on motivational
interviewing (MI) and focused on reducing drug use, with
HIV risk behaviors as a secondary behavioral target [15].
At 3-month follow-up, participants were re-randomized
to receive either an adapted motivational enhancement
therapy (AMET) booster or EUC. At 12-month follow-up,
the therapist-delivered BI was associated with reduced
number of days using any drug and reduced weighted drug
days (the number of days using any drug, weighted by the
number of drugs used each day). Both TBI and CBI contrib-
uted to fewer cannabis use days compared with EUC. The
effects of boosters were non-significant [14].
Despite the promising findings of HealthiER You, the ef-
fectiveness of BIs for reducing substance use [8,16] in di-
verse health-care settings remains equivocal. Most
previous drug-focused BIs were delivered in primary care
settings where the severity of substance use problems tends
to be low [17], which may account for a failure to detect
significant intervention effects in some studies. One notable
exception is Project QUIT [6], which was effective in reduc-
ing drug use. By contrast, utilizing an urban ED provided
HealthiER You opportunities to reach at-risk populations
[18] that may be more likely to benefit from brief interven-
tions [8]. To address these inconsistencies, studies are
needed to explore potential moderators of BI effectiveness
to establish for whom BIs might bemost effective, including
critical demographic factors such as age, race and sex. For
example, alcohol and cannabis use both typically peak dur-
ing the early to mid-20s and are most common in males
andwhite individuals [19]. Within urban, under-resourced
communities, however, cannabis is highly prevalent [20].
In addition to alcohol and cannabis use being highly co-
morbid [21], anxiety symptoms also commonly co-occur
with both alcohol and cannabis use and are associated
with greater impairment than substance use alone [21];
as such, it is important to disentangle the processes that
are shared versus unique among these co-occurring prob-
lems. Competing perspectives have been used to account
for the comorbidity between anxiety and substance use dis-
orders (SUD): (1) anxiety symptomology promotes SUDs,
(2) SUDs promote anxiety problems, (3) a third common
factor promotes both anxiety and problematic substance
use and (4) there are bidirectional effects of anxiety and
substance use on one another [22]. Given these complexi-
ties, longitudinal studies are necessary to clarify how these
processes ‘travel together’ over time. While there is some
evidence that anxiety can moderate the effectiveness of
cannabis treatment [22], no studies have tested whether
BIs designed to reduce drug use can have positive collateral
effects by simultaneously reducing parallel trajectories of
alcohol use and symptoms of anxiety. This information
would shed light on the extent to which efficacious drug-
focused BIs contribute to positive mental health outcomes
broadly or have specific effects only on drug use, which
would imply the need for tailoring of BIs towards alcohol
versus cannabis use versus mental health coping skills
more specifically.
To address these gaps in the literature, we used data
from HealthiER You [14] to examine trajectories of alcohol
use, cannabis use and anxiety during a 12-month period
among drug-using adults presenting to an ED located in a
predominately low-income, urban community who were
randomly assigned to receive CBI, TBI or EUC. Next, we in-
vestigated whether TBI or CBI (relative to EUC) was related
to greater reductions in alcohol use, cannabis use or anxi-
ety symptomswithin a parallel process latent growth curve
modeling (LGCM) framework that accounted for overlap of
these outcomes. The use of LGCM enabled us to explore the
unique variation in rates of alcohol use, cannabis use and
anxiety symptoms over three follow-up periods (baseline,
and 3-, 6- and 12-month) while simultaneously account-
ing for overlap of these processes [23]. Finally, we tested
whether the effectiveness of TBI or CBI (relative to EUC)
was moderated by sex, race or age. While prior work using
data from HealthiER You [14] reported main outcomes, it
did not account for the overlap in cannabis use, alcohol
use and anxiety symptoms and did not explore moderators
of treatment effectiveness. We hypothesized that both BIs
(i.e. TBI and CBI) relative to EUC would be related to
greater rates of reduction in all three processes—alcohol
use, cannabis use and anxiety symptoms, given previous
findings that HealthiER You BIs reduced cannabis use [14]
and that cannabis use, alcohol use and anxiety tend to
co-occur, such that improvements in one outcome may
contribute to improvements in the others. Because no prior
studies have explored potential moderation of parallel tra-
jectories of these processes, we did not have a priori hypoth-
eses about how sex, age or race might moderate the
effectiveness of TBI and CBI on intervention outcomes.
METHODS
Study design
The design, procedures, sample and primary and second-
ary outcomes of theHealthiERYou trial have been described
in detail in prior publications [14,15,24]. Briefly, the trial
involved a 3 × 2 factorial design where participants were
initially randomized to one of three conditions delivered
at the baseline ED visit: (1) 30-minute CBI, (2) 30-minute
TBI or (3) EUC (review of health resources brochures in
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the ED, exceeding the standard of care) (see Bonar et al.
[24], Table 1, for detailed description of the interventions).
After a 3-month follow-up assessment, participants were
then randomized to receive an adapted motivational en-
hancement therapy (AMET) booster or EUC-B (B: Booster
review of health brochures) (see Blow et al., [14] for further
description of AMET procedures). Follow-up staff and
3-month therapists were blinded to baseline condition
assignment. Outcomes were measured at 3, 6 and 12
months after baseline enrollment. Procedures were ap-
proved by the University of Michigan and Hurley Medical
Center Institutional Review Boards and a Certificate
of Confidentiality was provided by the National Institutes
Health.
Study setting and recruitment
Recruitment and baseline intervention delivery took place
at the Hurley Medical Center Emergency Department
(ED) in urban, Flint, Michigan from February 2011 to
August 2012. Research assistants screened patients aged
18–60 years who were identified through the electronic
medical record in the ED. After providing informed con-
sent, patients completed screening measures to determine
randomized controlled trial (RCT) eligibility (exclusions in-
cluded psychosis, medical instability, in police custody,
seeking care for suicidal ideation or acute sexual assault,
non-English-speaking or illiterate, severe hearing or visual
impairment). Compensation for the 15-minute screening
survey was a $1.00 gift (e.g. puzzle books, lotion). To be el-
igible for inclusion in the study, participants were required
to have a Specific Substance Involvement score ≥ 4 for any
illicit or misused prescription drug (i.e. stimulants,
sedatives, narcotics) within the past 3 months on the Alco-
hol, Smoking and Substance Involvement Screening Test
(ASSIST [25]). Those agreeing to participate provided a
second-stage informed consent and completed additional
baseline survey measures and a time-line follow-back
[26] interview plus a urine drug test (see [14,24] for more
details).
Interventions
The interventions and EUC have been previously described
in detail [14,15,24]. Briefly, the interventions were
grounded in motivational interviewing [27], with parallel
content in theCBI andTBI. Interventions usedMI strategies
to address participants’ drug use, as well as alcohol
consumption when relevant, and HIV risk behaviors. The
interventions included identifying participants’ strengths
and goals while addressing drug use via tailored exercises
and feedback. After each baseline BI, participants received
a summary ‘change plan’ that was based on elements se-
lected during the intervention (e.g. strengths, tools for
change, etc.), as well as resource pamphlets (e.g. housing,
food, etc.).
In the CBI, participants used a touchscreen tablet with
audio via headphones that included still and moving im-
ages and interactive vignettes and exercises led by a virtual
counselor, using tailored reflections. The TBI was delivered
by Master’s-level therapists, trained in MI by study investi-
gators, using a touchscreen tablet to guide the session and
maintain intervention fidelity in the chaotic ED environ-
ment where interruptions for medical care are common.
The TBI covered similar content as the CBI, including fo-
cusing on goals, benefits of change, etc.
Table 1 Descriptive statistics for main outcome variables of cannabis use, alcohol use and anxiety symptoms in the whole sample and






N Mean SD n Mean SD n Mean SD n Mean SD
Alcohol use (baseline) 780 5.08 7.22 266 4.94 7.04 257 4.75 6.62 257 5.56 7.94
Alcohol use (3-month follow-up) 628 5.49 7.69 223 5.35 6.96 199 5.21 8.01 206 5.92 8.13
Alcohol use (6 month follow-up) 659 4.25 6.13 234 4.63 6.24 208 3.95 5.99 217 4.14 6.14
Alcohol use (12-month follow-up 679 4.12 6.43 233 4.46 6.53 221 3.61 6.15 225 4.27 6.57
Cannabis use (baseline) 780 13.06 11.70 266 13.69 11.76 257 11.94 11.65 257 13.53 11.65
Cannabis use (3-month follow-up) 628 13.25 12.06 223 14.39 12.14 199 11.63 11.73 206 13.57 12.16
Cannabis use (6-month follow-up) 659 12.28 12.17 234 13.80 12.53 208 10.44 11.73 217 12.40 12.02
Cannabis use (12-month follow-up) 679 12.46 12.32 233 14.06 12.54 221 9.98 11.42 225 13.23 12.61
Anxiety symptoms (baseline) 778 0.93 1.03 264 0.88 1.01 257 0.95 1.02 257 0.95 1.07
Anxiety symptoms (3-month follow-up) 628 1.00 1.05 223 1.03 1.02 199 0.98 1.10 206 0.99 1.04
Anxiety symptoms (6-month follow-up) 659 0.86 0.96 234 0.92 0.97 208 0.83 1.04 217 0.81 0.88
Anxiety symptoms (12-month
follow-up)
679 0.81 0.95 233 0.85 0.97 221 0.82 0.97 225 0.75 0.91
SD = standard deviation.
© 2019 Society for the Study of Addiction Addiction, 115, 158–169
Laura E. Drislane et al.160
At 3months, a 40-minute AMETsession was also deliv-
ered by Master’s-level therapists. This session involved a re-
view of participants’ substance use from the past 3 months,
which assisted with tailoring the session that was also
computer-guided to support therapists in moving through
the intervention components. Therapists delivering the
TBI and AMET passed proficiency thresholds determined
using the Motivational Interviewing Treatment Integrity
Code (MITI Moyers et al., unpublished; Motivational
Interview Adherent summary score of 99 and 97% for
AMET [14]).
At both time-points, the EUC condition involved
reviewing a local health resource brochure and HIV pre-
vention information. This information was also given to
participants in the other conditions at both baseline and
follow-up visits to control for information receipt. Response
rates were greater than 80% for all follow-up periods
(3 months: 81%, 6 months: 85%, 12 months: 87%) and
were similar in all three intervention groups (CBI, TBI,
EUC) [14,24].
Measures
Outcome measures included (a) past 3-month alcohol use
severity as measured by the 10-item Alcohol Use Disorders
Identification Test (AUDIT [28]), which includes frequency
of use, average consumption and binge drinking alongwith
seven consequence items (baseline α = 0.89, 3-month
α = 0.90, 6-month α = 0.87, 12-month α = 0.88), (b) past
30-day cannabis use frequency as measured by the Na-
tional Survey on Drug Use and Health (NSDUH) CAI Spec-
ifications for Programming [29] and (c) past-week anxiety
symptoms as measured by a three-item anxiety subscale of
the Brief Symptom Inventory-18 (BSI-18 [30]) (baseline
α = 0.79, 3-month α = 0.83, 6-month α = 0.82, 12-month
Figure 1 Joint process model showing that alcohol use, cannabis use and anxiety levels decreased significantly across thewhole sample from baseline
to 12-month follow-up. ***P< 0.001. Model fit statistics: comparative fit index (CFI) = 0.94; Taylor–Lewis Index (TLI) = 0.92, root mean square error
of approximation (RMSEA) = 0.06, standardized root mean square residual (SRMR) = 0.05. Standardized values reflect Z-scores. Overall, throughout
the whole sample, there was a reduction in alcohol use across the four time-points, with significant variance in both starting levels (intercept) and linear
change (slope): means: slope, B =0.04, standard error (SE) = 0.01, P< 0.001, intercept, B = 0.96, SE = 0.04, P< 0.001; variances: slope, B = 0.01,
SE = 0.006, P< 0.05. Intercept, B = 0.66, SE = 0.06, P< 0.001. There was also a reduction in cannabis use across time, with significant variance in both
starting levels (intercept) and linear change (slope): means: slope, B =0.18, SE = 0.11, P = 0.11, intercept, B = 13.08, SE = 0.40, P< 0.001; variances:
slope, B = 2.63, SE = 0.93, P< 0.01. Intercept, B = 86.07, SE = 5.20, P< 0.001. There was a significant correlation between the starting levels of anxiety
and alcohol use (r = 0.31, P< 0.001), but not between anxiety and cannabis use or between alcohol and cannabis use. Finally, there were correlations
between slope factors (i.e. correlation in linear change): alcohol and cannabis use, r = 0.35, P < 0.05; alcohol use and anxiety: r = 0.47, P < 0.05;
cannabis and anxiety: r = 0.42, P < 0.05
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α = 0.81). These measures have well-established validity
[31–33].
Analytical plan
Aim 1: Explore trajectories of alcohol use, cannabis use and
anxiety during a 12-month period
We used parallel process latent growth curve modeling
(LGCM) in Mplus version 7.2 with full information maxi-
mum likelihood estimation with robust standard errors
based on a covariance matrix generated from multiple co-
variates (i.e. age, sex, race) to account for any missing
data [34]. Scores for alcohol use, cannabis use and anxiety
symptoms at baseline, 3-, 6- and 12-month assessments
were used as indicators for the intercept (starting values)
and slope (linear change) factors for each process, with
baseline set as the intercept. The slope and intercept factors
for each process (i.e. alcohol use, cannabis use and anxiety)
were allowed to covary, to take into account the ‘parallel’
or ‘joint’ nature of the processes unfolding over time at
the latent level (but not at the observed indicator level),
and each slope factor was regressed onto each of the three
intercept factors. All models also accounted for subsequent
AMET randomization [14]. Comparative fit index (CFI: cut-
off value 0.95) and root mean square error of approxima-
tion (RMSEA: cut-off value 0.06) were used to assess model
fit [35].
Aim 2: Impact of intervention on reductions in alcohol use,
cannabis use and anxiety and potential moderation by sex, age
and race
To explore the main effects of the interventions and poten-
tial moderation by sex, age and race, we tested a single
path model in Mplus where we regressed slope and inter-
cept factors onto intervention conditions (TBI relative to
EUD and CBI relative to EUD) and interaction terms be-
tween intervention condition (i.e. TBI or CBI relative to
EUD) with sex, race and age. An intent-to-treat approach
was used to include all available data for all participants
who were randomized. We probed significant interactions
Table 2 Main and moderating effects of intervention condition and sex, age, and race on linear reduction in concomitant cannabis use,
alcohol use and anxiety.
Slope factors
Cannabis Alcohol Anxiety
B (SE) β P B (SE) β P B (SE) β P
Main effects
Male 0.07 (0.40) 0.02 0.871 0.34 (0.19) 0.16 0.070 0.06 (0.03) 0.20* 0.023
Age 0.001 (0.02) 0.001 0.998 0.01 (0.01) 0.15 0.065 0.003 (0.001) 0.18* 0.023
White 0.01 (0.38) 0.003 0.981 0.17 (0.17) 0.08 0.307 0.03 (0.03) 0.10 0.233
TBI 1.01 (0.38) 0.29* 0.007 0.02 (0.19) 0.01 0.929 0.06 (0.03) 0.17* 0.039
CBI 0.38 (0.37) 0.11 0.304 0.10 (0.18) 0.05 0.569 0.04 (0.03) 0.13 0.157
Effects of starting levels
Cannabis intercept 0.03 (0.02) 0.16 0.164 0.004 (0.007) 0.03 0.586 0.001 (0.001) 0.09 0.203
Alcohol intercept 0.004 (0.03) 0.01 0.883 0.09 (0.03) 0.47*** 0.001 0.001 (0.002) 0.05 0.564
Anxiety intercept 0.68 (0.35) 0.35 0.052 0.49 (0.18) 0.39** 0.006 0.03 (0.04) 0.14 0.518
Interaction effects
TBI × male 0.13 (0.52) 0.03 0.808 0.66 (0.26) 0.22* 0.010 0.05 (0.04) 0.10 0.217
CBI × male 0.37 (0.53) 0.08 0.485 0.02 (0.27) 0.01 0.947 0.04 (0.04) 0.09 0.272
TBI × age 0.04 (0.02) 0.16* 0.039 0.02 (0.01) 0.09 0.202 0.001 (0.002) 0.01 0.947
CBI × age 0.001 (0.02) 0.002 0.985 0.02 (0.01) 0.12 0.084 0.001 (0.002) 0.91 0.928
TBI × white 0.45 (0.51) 0.13 0.268 0.24 (0.14) 0.08 0.326 0.07 (0.04) 0.16 0.069
CBI × white 0.27 (0.43) 0.06 0.606 0.05 (0.25) 0.02 0.842 0.003 (0.04) 0.01 0.937
R2 0.15** 0.33*** 0.29***
***P < 0.001; **P < 0.01; *P < 0.05. TBI = therapist-based intervention; CBI = computer-based intervention; SE = standard error. Model fit statistics: com-
parative fit index (CFI) = 0.93, Taylor–Lewis Index (TLI) = 0.91, root mean square error of approximation (RMSEA) = 0.04, standardized root mean square
residual (SRMR) = 0.03. Effects of interventions are relative to a no-intervention control groupwithin a randomized controlled trial (RCT) design. Income was
not a significant predictor in the model and its inclusion did not change the findings presented. Thus, consistent with the original publication using this inter-
vention sample, it was not included in the final model (Blow et al. [14]). All models also accounted for subsequent AMET randomization (Blow et al. [14]).
Because depression and anxiety are often comorbid, we controlled for the effects of depression symptoms at baseline on all intercept and slope factors. Higher
levels of depression were related to higher starting levels (i.e. intercept factor scores) of anxiety and alcohol use and significant increases (i.e. slope factor) in
alcohol use over time (results available on request). Finally, each intercept factor was also simultaneously regressed onto sex, age and race. Starting levels
of cannabis use and alcohol use were higher in males, starting levels of alcohol use were lower in white participants, starting levels of cannabis were higher
in younger participants and starting levels of anxiety were higher in older participants (results available on request).
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by separately exploring slopes for males versus females,
white versus non-white participants, and different ages.
RESULTS
Descriptives
Participants were aged 31 years on average [range = 18–
60; standard deviation (SD) = 10.9]; 44% (n = 347) were
male and 52% (n = 407) were black (see [14] for further
details). At baseline, 66% of the sample (n = 513) reported
cannabis use problems (ASSIST score ≥ 4), 23% (n = 179)
displayed harmful alcohol use (AUDIT score ≥ 8) and 25%
(n = 196) displayed significant symptoms of anxiety (BSI
anxiety score> 1.33, equivalent to a T-score> 63 among
both men and women). There were no statistical differ-
ences in baseline demographic, drug use or anxiety charac-
teristics across intervention groups (CBI, TBI, EUC). Table 1
presents descriptive statistics for alcohol use, cannabis use
and anxiety symptoms across all four assessment points.
Aim 1: Trajectories of alcohol use, cannabis use and anxiety
during a 12-month period
Figure 1 displays the longitudinal trajectories of alcohol
use, cannabis use and anxiety after accounting for their
shared overlap across the whole sample from baseline to
12-month follow-up [CFI = 0.94; Taylor–Lewis Index
(TLI) = 0.92, RMSEA = 0.06, standardized root mean
square residual (SRMR) = 0.05]. Alcohol use, cannabis
use and anxiety symptoms all showed significant reduc-
tions over the 1-year follow-up. In support of these pro-
cesses as being overlapping or ‘joint processes’, higher
starting levels (i.e. intercept factors) of anxiety and alco-
hol use were correlated, and there were significant
correlations between slope factors (i.e. correlation in
Figure 2 Cannabis use showed a significant reduction over time from baseline to 12 months in the therapist-based intervention (TBI) group.
*P < 0.05, NS = non-significant. There was a significant linear reduction in cannabis use over time in the TBI group [B = 0.49, standard error
(SE) = 0.20, P < 0.05] but not the control group (B = 0.13, SE = 0.20, P = 0.50)
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rates of linear change) for all three variables. That is,
the rate of reduction for all three processes was corre-
lated (see Fig. 1).
Aim 2: Impact of intervention on reductions in alcohol use,
cannabis use and anxiety symptoms and potential moderation
Table 2 presents results from the single model regressing
slope factors from the parallel process growth model onto
the main and moderating effects of intervention condition
(TBI or CBI relative to EUC), sex, age and race on linear
change. The model also controlled for main effects of sex,
age and race on starting levels of substance use and anxiety
(i.e. intercept factors) (CFI = 0 .93, TLI = 0.91,
RMSEA = 0.04, SRMR = 0.03). First, we found a main ef-
fect of TBI on cannabis use slope. Specifically, there was a
significant reduction in cannabis use over time in the TBI
group, but not the EUC group (Fig. 2). Similarly, there
was a main effect of TBI relative to EUC on reduction in
anxiety levels from baseline to 12-months (Table 2; Fig. 3).
There were no unique main effects of CBI relative to EUC
on the rate of change in any of the three parallel processes
of alcohol use, cannabis use and anxiety symptoms, taking
into account the overlap of these processes.
In the same model, we included interaction terms be-
tween intervention condition and sex, age and race.
First, we found that sex moderated the effectiveness of
TBI on the rate of reduction in alcohol use (Table 2).
We probed this interaction by exploring rates in reduc-
tion in alcohol use among males and females separately.
Relative to the EUC condition, we found a significant lin-
ear reduction in the rate of alcohol use over time among
males, but not females, in the TBI group (see Fig. 4).
Secondly, the effect of TBI on the slope of cannabis use
was moderated by age. We explored this interaction
among four different age groups. We found that only
participants aged 18–25 years who received TBI, but
not aged 26–35, 36–46 or 46 and older, showed signif-
icant reductions in cannabis use relative to EUD. We
Figure 3 Anxiety level showed a significant reduction over time from baseline to 12 months in the therapist-based intervention (TBI). *P < 0.05,
NS = non-significant. There was a significant linear reduction in level of anxiety over time in the TBI group [B = 0.04, standard error (SE) = 0 .02,
P < 0.05] but not the control group (B = 0.006, SE = 0.02, P = 0.74)
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found no significant moderation of the effects for the
CBI, or of either TBI or CBI by race (Fig. 5).
DISCUSSION
Alcohol use, cannabis use and anxiety symptoms often co-
occur and it is critical to study how they ‘travel together’
and the extent to which BIs aimed at reducing drug use
that can be implementedwith high fidelity and accessibility
might exert collateral effects on alcohol use and anxiety. In
this novel study that incorporated sophisticated quantita-
tive modeling techniques using data from a large sample
of low-income, urban adults who presented to an ED, we
examined 12-month trajectories of alcohol use, cannabis
use and anxiety following completion of drug-focused TBI
or CBI intervention modalities compared to EUC. We
showed that TBI was effective in reducing cannabis use
and anxiety symptomatology. Moreover, we found that
TBI was effective in reducing alcohol use specifically
among males and that younger participants benefited the
most from the effects of TBI in reducing cannabis use. We
highlight three main implications from these findings.
First, we found that TBI was an effective intervention
for reducing harmful drug and alcohol use, as well as co-
occurring anxiety symptoms, among ED patients. These re-
sults indicate that successfully intervening on drug use can
positively impact comorbid alcohol use and anxiety symp-
toms, suggesting that concurrent or integrated treatments
Figure 4 Alcohol use showed a significant reduction over time from baseline to 12 months among males in the therapist-based intervention (TBI).
**P < 0.01, *P < 0.05, NS = non-significant. There was a significant linear reduction in level of alcohol use over time among males in the TBI group
[B = 0.60, standard error (SE) = 0.19, P < 0.01) but not the control group (B = 0.15, SE = 0.18, P = 0.40) Among females, there was a slight
decrease in alcohol use in the control group (B = 0.21, SE = 0.11, P < 0.05), but the rate of alcohol use among females in the TBI group did
not change significantly (B = 0.08, SE = 0.12, P = 0.52)
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for anxiety-related problems may not be necessary for
some individuals [36]. Although CBI reduced cannabis
use days when examined as a sole outcome [14], CBI rela-
tive to EUC did not result in significant reductions in sever-
ity of alcohol use, cannabis use and anxiety when
examined as simultaneous outcomes. While CBI offers
many advantages, such as convenience and low costs, as-
pects of communicating in-person with a therapist during
a single session may facilitate enhanced change processes
in multiple co-occurring outcomes beyond the scope of a
self-directed, single session computer program. Additional
research is needed to compare effectiveness of therapist
versus computer-based BIs directly and among more repre-
sentative samples.
Secondly, reductions in alcohol use after TBI were found
among men, but not women. Although females showed
decreasing alcohol use during the 12 months following
TBI, the extent of their declines in alcohol use were much
smaller than males. By the 12-month follow-up, frequency
of alcohol use remained higher among males compared to
females, but the sex gap significantly narrowed as a result
of TBI. This is consistent with findings from a systematic re-
view of brief alcohol interventions in primary care settings
[37], which reported evidence for clear reductions in
Figure 5 Participants aged 18–25 years benefited most from the therapist-based intervention (TBI) relative to other age groups. *P < 0.05,
†P < 0.10. The figure shows linear change in cannabis usage among individuals within the TBI group divided into four age categories: 18–25
(n = 101), 25–35 (n = 76), 36–45 (n = 45) and 46 years and older (n = 35). Individuals aged 18–25 years who received TBI showed a significant
reduction in cannabis usage [B = 0.78, standard error (SE) = 0.31, P < 0.05]; individuals aged 26–35 within the TBI group also showed a modest
reduction in cannabis use, but was not significant (B = 0.64, SE = 0.38, P = 0.09); individuals aged 36–45 years within the TBI group did not show
a significant change in usage (B = 0.40, SE = 0.50, P = 0.43); finally, individuals aged 46 years or older within the TBI group actually showed a slight
increase in cannabis use but was not significant (B = 0.54, SE = 0.31, P = 0.09)
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alcohol use following BI for men, but not women. The
mechanism driving this sex difference is probably lower
rates of consumption resulting in floor effects; however,
more research is needed to examine ways to enhance inter-
ventions for women (e.g. greater inclusion of sex-specific
consequences) [38]. In contrast to sex differences in inter-
vention effects, race did not impact linear reductions in
cannabis use, alcohol use or anxiety. This is notable, given
the racial diversity of the present sample. Many previous
BI RCTs have utilized primarily white samples (however,
see [39]), which has limited the ability to examine system-
atic differences in intervention effectiveness as a function of
race or ethnicity [37].
Thirdly, significant reductions in cannabis use in the
TBI condition were specifically found among young
adults between the ages of 18 and 25 years. This finding
is critical from a developmental perspective, because sub-
stance use tends to peak during the transition to adult-
hood (i.e. aged 18–25 years [19]). This developmental
period also coincides with the typical onset of symptoms
of substance use disorder (SUD [20]). Approximately 5.3
million—or one in seven—young adults in the United
States aged 18–25 years have a SUD, which represents
the largest proportion of individuals with problematic
substance use [2,40]. Thus, findings from the present
study highlight the potential impact of the HealthiER
You TBI on reducing cannabis use among young adults
at a critical juncture in development. The ED may be
an especially important venue for SBIRT with drug-using
emerging adults who may not otherwise receive inter-
ventions, because the ED is a frequent source of care to
uninsured and under-insured populations [41,42], and
emerging adults often lack connection to health-
care providers when transitioning out of pediatric medi-
cine [42–45].
Strengths and limitations
A major strength of the present study is its methodological
approach. Given the high co-occurrence of alcohol use,
cannabis use and anxiety, examining their parallel trajecto-
ries provides valuable information pertaining to the utility
of TBI and CBI for drug use in impacting not only substance
use, but also mental health outcomes. We also were able to
examine potential moderators of the effectiveness of BIs,
providing more information about which interventions
are effective in reducing alcohol use, cannabis use and anx-
iety, and for whom. Although a strength of the study is the
ED sample of racially diverse, low-income adults the find-
ings, including moderation effects, require replication prior
to generalization to other populations. Further, this study
was conducted among adults screening positive for drug
use (primarily cannabis), and findings may not generalize
to samples screening positive for alcohol use or other men-
tal health concerns. In addition, dismantling studies may
provide insights into which components of BIs contribute
to improvements acrossmental health outcomes, including
anxiety and substance use, versus those that are specific to
reducing drug and alcohol use.
CONCLUSIONS
In summary, findings from the present study not only high-
light the potential utility of a motivational interviewing-
based TBI focused on reducing drug use for also reducing
alcohol use, cannabis use and anxiety symptoms up to
12 months following the intervention, but also demon-
strate the importance of examining subgroup differences,
such as sex and age, in relation to intervention outcomes.
TBIs implemented through the HealthiER You study offer
a relatively time-efficient way to reduce substance use
and improve anxiety symptoms.
Clinical trial registration
Name of trial: HealthiER You: Optimizing Screening, Brief
Interventions, and Referral to Treatment (SBIRT) in the
Emergency Department. Registration number:
NCT01113190. Registration date: 20 April 2010. Recruit-
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